Imraldi (Adalimumab)

Adalimumab is a monoclonal antibody that specifically binds to both soluble and membrane‑bound TNF‑α. By neutralising this cytokine, it blocks the cascade of inflammatory signals that lead to tissue damage, thereby decreasing pain, swelling and disease progression in affected organs.

The dosing regimen for Imraldi is determined by the prescribing clinician based on the patient’s condition, weight, and response to therapy. Healthcare professionals follow approved guidelines and adjust the dose as needed; patients should follow the prescriber’s instructions exactly.

The safety of adalimumab in pregnancy and lactation has not been fully established. It is classified as pregnancy category unknown, and clinicians weigh potential benefits against risks. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To request Imraldi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Imraldi contains the same active molecule, adalimumab, as other branded products like Humira. Clinical efficacy and safety are comparable, while differences may exist in formulation, packaging, and pricing. Choice of product often depends on supply chain considerations, regulatory approvals and institutional contracts.

Imraldi must be stored refrigerated between 2 °C and 8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If a temperature excursion occurs, consult the product’s stability guidelines before use.

Imraldi is supplied as a 40 mg solution for subcutaneous injection. The patient or a healthcare professional injects the dose under the skin, typically in the abdomen, thigh or upper arm, following aseptic technique and the prescriber’s dosing schedule.

Serious risks include severe infections such as tuberculosis or opportunistic fungal infections, possible development of malignancies (e.g., lymphoma, skin cancer), worsening heart failure, and rare demyelinating disorders. Patients should be monitored regularly for signs of infection, malignancy and cardiac symptoms.

Imraldi is contraindicated in patients with known hypersensitivity to adalimumab or any excipients, and in those with active serious infections. Caution is advised for individuals with uncontrolled heart failure, demyelinating disease, or a history of malignancy. The prescriber must evaluate each patient’s medical history before initiating therapy.